首页> 外文OA文献 >BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

【2h】

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

机译：用酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的BCR-aBL激酶结构域突变分析：代表欧洲白血病网的专家小组的建议。

页面导航

著录项
相似文献
相关主题

著录项

作者
Soverini S; Hochhaus A; Nicolini FE; Gruber F; Lange T; Saglio G; Pane F; M?ller MC; Ernst T; Rosti G; Porkka K; Baccarani M; Cross NC; Martinelli G;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. [J] . Soverini S, Hochhaus A, Nicolini FE, Blood: The Journal of the American Society of Hematology . 2011,第5期

机译：酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的BCR-ABL激酶结构域突变分析：代表欧洲LeukemiaNet的专家小组的建议。
2. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. [J] . Soverini S, Hochhaus A, Nicolini FE, Blood: The Journal of the American Society of Hematology . 2011,第5期

机译：酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的BCR-ABL激酶结构域突变分析：代表欧洲LeukemiaNet的专家小组的建议。
3. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. [J] . Jabbour E, Jones D, Kantarjian HM, Blood: The Journal of the American Society of Hematology . 2009,第10期

机译：伊马替尼治疗失败后，使用第二代酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的长期预后可通过BCR-ABL激酶域突变的体外敏感性来预测。
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Clinical Trials and Observations: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations [O] . Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, -1

机译：临床试验和观察：伊马替尼治疗失败后用第二代酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的长期预后可通过BCR-ABL激酶域突变的体外敏感性来预测
7. 1 BCR-ABL KINASE DOMAIN MUTATION ANALYSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS – RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIANET [O] . Giovanni Martinelli, Simona Soverini Phd 2011

机译：用酪氨酸激酶抑制剂治疗慢性髓性白血病患者的BCR-aBL激酶域突变分析 - 以欧洲白血病患者为代表的专家小组的建议

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

著录项

相似文献

相关主题

期刊订阅